Saturday, November 7, 2026

Back to the front page

From X

@calvinblissett 2 clicks

Calvin Blissett on X

$TTAM: Stan Druckenmiller and Chris Hohn long concrete. Titan America is a vertically integrated East Coast cement/building-materials platform with leading positions in Florida (~31%), Virginia/North Carolina (~30%) and Metro New York (~24%). Its moat is physical: scarce permitted cement capacity, quarries, marine terminals, rail, ready-mix and downstream distribution. The business generated $1.66B of revenue and $390M of adjusted EBITDA in 2025, and 2025 ROCE was 19.5%. The major change in 2026 is Keystone. Titan closed the $310M acquisition in May, adding 990K tons of clinker capacity and >50 years of mineral reserves. Keystone contributed ~$20M of Q2 revenue; Titan is targeting ≥$30M of annual run-rate synergies by 2029. Mid-Atlantic Q2 revenue/EBITDA rose 27%/30%, partly driven by Keystone, while Florida EBITDA fell 19% because of Pennsuco maintenance and import-logistics disruptions. The construction backdrop is softer than the old table suggested: U.S. construction spending was down 3.8% YoY in July 2026, and ACA expects cement consumption to fall 2.5% in 2026 before turning positive in 2027. The bright spots are data centers and infrastructure: July 2026 AIA consensus calls for data-center construction growth of 33% in 2026 and 24.7% in 2027, while nonresidential overall is -0.3% / +3.0%. At $13.85 on September 25, TTAM has ~$2.55B of market cap and ~$3.09B of EV against $393.7M of TTM adjusted EBITDA, or ~7.9x EV/EBITDA. A reference peer group is around ~12.4x. Your replacement-cost framework of ~$4.2B ex-logistics therefore equates to ~$1.1B above current EV; after net debt, roughly ~$3.7B of equity value versus ~$2.6B today. The key debate is no longer whether Keystone is cheap on capacity—it is whether Titan can actually turn that capacity into normalized EBITDA through utilization, pricing and network synergies.

Problems at Twist Bioscience (TWST)

Twist Bioscience’s $200 rebound followed an Anthropic-linked short squeeze, yet its DNA and protein services face broad competition while…

VSH Earnings Review

Vishay reported record Q3 revenue of $979 million, up 24%, and guided Q4 to about $990 million as rising backlog and margins contrast with…

New Ideas From The Road

Aurelion Research increased healthcare exposure and sees opportunities in banking and defense, alongside research on Alcoa, Nike, ONON and…

AAP · long

Advance Auto Parts INC

Advance Auto Parts, AAP, is presented as a long idea following prior write-ups at $48.81 per share in January 2025.

Site Centers (NYSE:SITC)

Site Centers' $3 per-share return-of-capital distribution and December delisting leave a discounted liquidation stub, with two properties…

Stevanato down 30%. Yikes.

Stevanato fell 30% after forecasting low-single-digit 2027 growth as lower Nexa syringe volumes from a GLP-1 customer offset solid Q3…

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 109

X accounts we follow

Every account on this site, hand-picked.

91 accounts

Investor letters we follow

359 firms

Sectors

Ordered by how often our editor reaches for them.